Condition category
Cancer
Date applied
02/02/2013
Date assigned
21/02/2013
Last edited
21/02/2013
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Uterine fibroids are a common gynaecological condition affecting women of reproductive age. Approximately half of women with fibroids experience symptoms including heavy menstrual bleeding, abdominal pain and pressure, all of which can impact on quality of life. The choice of treatment is between surgical removal of the fibroids / womb (myomectomy or hysterectomy) or a minimally invasive treatment called uterine artery embolisation (UAE).
UAE is a minimally invasive interventional radiology procedure which blocks the blood vessels supplying the uterus. These vessels are accessed via arteries in the groin and using a small tube (angiographic catheter) to inject biodegradable particles into the arteries supplying the uterus. The fibroids fail to regain a blood supply and undergo necrosis (cell death).
Many different particulate agents are in use for UAE. The two agents in this study are Contour non-spherical polyvinyl alcohol (PVA) and Embozenes (Polyzene coated hydrogel microspheres). Both the embolic agents are safe and approved for use in uterine artery embolisation.
Non-spherical polyvinyl alcohol (PVA) has been used for more than two decades and is inexpensive. However this embolic agent has a tendency to clump and can block larger calibre vessels than the specified diameter of the particle. New calibrated particles have been developed which do not clump with claims that this is advantageous. The calibrated particles have a cost implication and yet there is no current evidence to back the manufacturers’ and physicians’ claims that they are superior to non-spherical PVA. Both the agents are tiny inert plastic beads that are designed to block blood flow within arteries. Both embolic agents contain particles that are of a similar size range (350 to 1100 micrometres).
As well as being minimally invasive, one of the advantages of UAE is its reduced cost compared with surgery. The results of the two particulate agents will be assessed comparing the improvement in the quality of life using validated QOL forms and fibroid infarction rates using routine contrast enhanced MRI scans at 6 months.

Who can participate?
Female patients aged 18-55 years with symptomatic fibroids admitted for uterine artery embolisation

What does the study involve?
Comparison of two embolic agents:
1. Contour Non-spherical polyvinyl alcohol (PVA). Boston Scientific, USA. CE 0197
2. Embozene Microspheres (calibrated hydrogel microspheres with polyzene coating). CeloNova Biosciences, USA. CE 0086
Aside from the difference in embolic particles used to block the arteries to the womb the rest of the clinical treatment is identical. Participants will be randomised to one embolic agent or the other.
The study processes: interventional procedure; clinical care; follow-up; and post procedure MRI scans, are already standard practice in our institution and identical between the two study groups.

What are the possible benefits and risks of participating?
There are no specific benefits to study participants. The treatment given to patients in either treatment arm of the study is equally effective in current medical practice. Patients will have the same care during the procedure and close follow-up whether entered into the study or not.
The substances injected are embolic agents consisting of inert plastic / polymer-based microspheres. Both embolic agents are CE marked and classed for commercial use for embolisation in uterine artery embolisation. There are procedural risks that are related to the angiographic study and vascular interventional techniques required to access the uterine arteries but are not specific to the embolic agents in this study. The risk benefit ratio of performing UAE has been well established and UAE has an excellent safety profile.

Where is the study run from?
This is a single centre study based at St George’s Healthcare NHS Trust in London.

When is the study starting and how long is it expected to run for?
The start date is January 2013 and the study will last approximately 2 years until the final participant completes 6 months follow-up.

Who is funding the study?
St George’s Healthcare NHS Trust, London, UK

Who is the main contact?
Dr Raj Das (Study coordinator / Principal Investigator)
drrajdas@gmail.com

Trial website

Contact information

Type

Scientific

Primary contact

Prof Anna-Maria Belli

ORCID ID

Contact details

Department of Radiology
St George's Healthcare NHS Trust
Blackshaw Road
London
SW17 0QT
United Kingdom

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

NRES study 12/LO/1581. Sponsor reference number: 12.0126. Study Protocol V1.1

Study information

Scientific title

Randomised controlled trial of Particles used in Uterine fibRoid Embolisation (PURE): Non-spherical polyvinyl alcohol versus calibrated hydrogel microspheres with polyzene coating

Acronym

PURE

Study hypothesis

PURE study is designed to detect differences in outcome (clinical and radiological) between uterine artery embolisation performed with non-spherical polyvinyl alcohol (Contour PVA) versus calibrated hydrogel microspheres with polyzene coating (Embozenes)

Ethics approval

NRES Dulwich, London, 11/01/2013, study reference: 12/LO/1581

Study design

Prospective single blinded randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Uterine fibroids (leiomyoma)

Intervention

Uterine artery embolisation performed using either:
1. Contour Non-spherical polyvinyl alcohol (PVA), Boston Scientific, USA. CE 0197

OR

2. Embozene Microspheres (calibrated hydrogel microspheres with polyzene coating), CeloNova Biosciences, USA. CE 0086

Intervention type

Other

Phase

Not Applicable

Drug names

Primary outcome measures

To confirm whether microsphere embolic particles (Embozenes) improve patient’s quality of life compared with the standard agent of non-spherical PVA (Contour PVA). This is measured using the validated Uterine Fibroid Symptom and Health-related Quality of Life questionnaire (UFS-QOL).

Secondary outcome measures

1. Contrast-enhanced MRI performed before and 6 months after UAE
2. Percentage Fibroid infarction - total fibroid burden and dominant fibroid infarction
3. Uterine and dominant fibroid volume reductions

Overall trial start date

01/01/2013

Overall trial end date

01/01/2015

Reason abandoned

Eligibility

Participant inclusion criteria

1. Symptomatic fibroids admitted for uterine artery embolisation
2. Female participants aged 18-55 years

Participant type

Patient

Age group

Adult

Gender

Female

Target number of participants

80

Participant exclusion criteria

1. Recent or ongoing pelvic inflammatory disease
2. Severe radiographic contrast medium allergy.
3. Significant adenomyosis, as identified by transvaginal ultrasound or MRI. Concurrent adenomyosis where fibroids are believed to the predominant cause of symptoms will be eligible.
4. Positive pregnancy test
5. Refusal to accept hysterectomy, in the event of an intra-operative complication.
6. Suspected malignancy
7. Age< 18
8. Unable to provide informed consent due to incapacity (as defined by Mental Capacity Act 2005 or Adults with Incapacity (Scotland) Act 2000.
9. A non English speaker where translation or interpretation facilities are insufficient to guarantee informed consent

Recruitment start date

01/01/2013

Recruitment end date

01/01/2015

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Department of Radiology
London
SW17 0QT
United Kingdom

Sponsor information

Organisation

St George's Healthcare NHS Trust (UK)

Sponsor details

c/o Ms Nadia Azzouzi
St George’s Joint Research Office
Ground Floor
Hunter Wing
St George’s University of London
Cranmer Terrace
Tooting
London
SW17 0RE
United Kingdom

Sponsor type

Hospital/treatment centre

Website

http://www.stgeorges.nhs.uk/

Funders

Funder type

Hospital/treatment centre

Funder name

St George’s Healthcare NHS Foundation Trust (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes